View CME-certified poster presentations and downloadable slides covering the most up-to-date clinical trial data on melanoma from the 2018 European Oncology Congress in Munich.
1.5 AMA PRA Category 1 Credit(s)™
Apr 15, 2019
Apr 15, 2020
Abstract #LBA44: Overall survival at 4 years of follow-up in a phase 3 trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)
Featured Expert: Reinhard Dummer, MD
Abstract #LBA47: Initial results from a phase 3b/4 study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511)
Featured Expert: Celeste Lebbé, MD
Abstract #1244O: KEYNOTE-022 Part 3: Phase 2 randomized study of 1l dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma
Featured Expert: Paolo A. Ascierto, MD
Abstract #1248PD: Efficacy of pembrolizumab (Pembro) in patients (Pts) with advanced melanoma with stable brain metastases (BM) at baseline: A pooled retrospective analysis
Featured Expert: Omid Hamid, MD
Abstract #LBA42: OpACIN-neo – A Multicenter Phase 2 Study to identify the Optimal neo-Adjuvant Combination scheme of Ipilimumab (IPI) and Nivolumab (NIVO)
Featured Expert: Christian U. Blank, MD, PhD
Abstract #LBA45: Poster Discussion Session: Phase 1b/2, Open Label, Multicenter, Study of the Combination of SD-101 and Pembrolizumab in Patients with Advanced Melanoma who are Naïve to Anti-PD-1 Therapy
Featured Expert: Antoni Ribas, MD, PhD
Paolo A. Ascierto, MDNational Tumor Institute - Fondazione G. Pascale
Christian U. Blank, MD, PhDNetherlands Cancer Institute
Amsterdam, the Netherlands
Reinhard Dummer, MDUniversity of Zurich Hospital
Omid Hamid, MDThe Angeles Clinic and Research Institute
Los Angeles, California, United States
Celeste Lebbé, MDHôpital Saint Louis
Antoni Ribas, MD, PhDUCLA Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
This activity is specifically designed for physicians, nurses, and other clinicians who are cancer specialists.
After successful completion of this educational activity, participants should be able to:
- Identify clinical trial data presented at 2018 European Oncology Congress in Munich
- Incorporate new findings presented in Munich into patient treatment regimens, where applicable
This educational activity is supported by grants from Bayer HealthCare Pharmaceuticals, Inc.; Bristol-Myers Squibb; and Merck and Co, Inc.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.
Method of Participation
Estimated time to complete activity: 1.5 hours
To contact Postgraduate Institute for Medicine please visit www.pimed.com.
Disclosure of Relevant Financial Relationships
Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Blank has disclosed that he received consulting fees from Bristol-Myers Squibb, Genmab, GlaxoSmithKline, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, and Roche. He also disclosed independent contracting for Bristol-Myers Squibb, Nanostring, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Dummer has disclosed intermittent, project-focused consulting and/or advisory relationships with Amgen, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi, Sun Pharma, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Hamid has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Merck, Novartis, and Roche/Genentech. He also received honoraria for promotional speaker’s bureaus from Amgen, Array Biopharma, Bristol-Myers Squibb, Novartis, and Roche/Genentech. He also disclosed independent contracting for his institution for AstraZeneca, Bristol-Myers Squibb, Celldex, Immunocore, Incyte, MedImmune, Merck, Merck Serono, Novartis, Pfizer, Rinat, and Roche/Genentech. Furthermore, he disclosed membership on advisory committees or review panels for Amgen, Bristol-Myers Squibb, Merck, Novartis, and Roche/Genentech. He has been speaking and teaching for Amgen, Array Biopharma, Bristol-Myers Squibb, Novartis, and Roche/Genentech. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Lebbé has disclosed that she has been on advisory boards for Aventis, Bristol-Myers Squibb, Merck, Merck Sharp & Dohme, Novartis, and Roche. Furthermore, she has been speaking and teaching for Bristol-Myers Squibb. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Ribas has disclosed board membership with PACT Pharma. He received consulting fees from Amgen, Bristol-Myers Squibb, Chugai, Genentech, Merck, Merck Sharp & Dohme, Novartis, and Roche. Furthermore, he disclosed ownership interest in Advaxis, Arcus, Bioncotech, Compugen, CytomX, Five Prime, FLX-Bio, ImaginAb, Isoplexis, Kite-Gilead, Lutris, Merus, PACT Pharma, Rgenix, and Tang Therapeutics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.
The employees of prIME Oncology have disclosed:
- Angela Zimmermann, PhD (scientific content manager) – worked on non–CME certified projects in the last 12 months supported by AstraZeneca, Merck, Novartis, and Pfizer
- Susan McKinney (editorial content reviewer) – no relevant financial relationships
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.